Technology | Breast Biopsy Systems | April 26, 2019

Hologic Launches Trident HD Specimen Radiography System

System features a bigger amorphous selenium direct capture imaging detector for complete imaging of larger breast surgical specimens

Hologic Launches Trident HD Specimen Radiography System

April 26, 2019 — Hologic Inc. announced global commercial availability of the Trident HD specimen radiography system. The next-generation solution delivers enhanced image quality, improved workflow and instant sample verification during breast-conserving surgeries and stereotactic breast biopsies.1

The Trident products use amorphous selenium direct capture imaging – the same detector technology used in Hologic’s 3Dimensions mammography system – to generate crisp, clear, high-resolution images. The new Trident HD system — which recently received U.S. Food and Drug Administration (FDA) clearance, a CE Mark in Europe and also launched in Canada – features a bigger detector that allows for complete imaging of larger breast surgical specimens, along with a wide range of surgical and biopsy samples.2

The system eliminates the need for clinicians to transport specimens for imaging. It also features an ergonomic design that is 37 percent smaller than the original Trident system, making it easy to maneuver in a crowded operating or procedure room. Prior mammography or biopsy images can be displayed on the same Trident HD high-resolution monitor to speed comparison and analysis, resulting in reduced procedure time and improved workflow.1 Additionally, an intuitive touchscreen interface and wireless integration supports advanced image sharing and seamless transfer of patient records to the facility’s picture archiving and communication system (PACS).

For more information: www.hologic.com

References

1. Wilson A. Trident 2.0 QUAL Qualitative Findings. Explore and identify the ideal breast biopsy verification system from the OR. Kadence International. July 2016.

2. Compared to original Trident system, which is not available in Europe

Related Content

A, Contrast-enhanced axial T1-weighted fat-saturated image from baseline MRI before initiation of neoadjuvant therapy shows irregular mass (arrow) in upper inner right breast corresponding to biopsy-proven carcinoma. B, Contrast-enhanced axial T1-weighted fat-saturated image from follow-up MRI performed 3 months after initiation of neoadjuvant therapy shows decrease in size of right breast cancer (arrow). C, Contrast-enhanced axial T1-weighted fat-saturated image 3 months after initiation of neoadjuvant the

A, Contrast-enhanced axial T1-weighted fat-saturated image from baseline MRI before initiation of neoadjuvant therapy shows irregular mass (arrow) in upper inner right breast corresponding to biopsy-proven carcinoma. B, Contrast-enhanced axial T1-weighted fat-saturated image from follow-up MRI performed 3 months after initiation of neoadjuvant therapy shows decrease in size of right breast cancer (arrow). C, Contrast-enhanced axial T1-weighted fat-saturated image 3 months after initiation of neoadjuvant therapy shows new mass (arrow) in upper outer left breast that was assessed as BI-RADS 4. Pathologic examination from MRI-guided core biopsy of new suspicious mass revealed benign usual ductal hyperplasia. No atypia or malignancy was identified. Image courtesy of American Roentgen Ray Society (ARRS), American Journal of Roentgenology (AJR)

News | MRI Breast | January 15, 2021
January 15, 2021 — According to ARRS' ...
A targeted intervention providing mammograms to hospitalized Medicaid patients can help patients complete overdue breast cancer screening

Getty Images

News | Mammography | January 14, 2021
January 14, 2021 — Completing cancer screening tests, such as...
DB-I website features new educational tools and streamlined user experience to improve access to medically sourced breast density content
News | Breast Density | January 13, 2021
January 13, 2021 — DenseBreast-info.org (DB-I) invites he
This cutting-edge technology assists radiologists in the interpretation of screening mammograms and allows them to diagnose breast cancer earlier and more accurately
News | Mammography | January 12, 2021
January 12, 2021 — Therapixel announced that...
World-first techniques for predicting breast cancer risk from mammograms that were developed in Melbourne could revolutionise breast screening by allowing it to be tailored to women at minimal extra cost

Getty Images

News | Mammography | January 06, 2021
January 6, 2021 — World-first techniques for predicting breast cancer risk from...
Transaction accelerates Hologic’s entry into oncology growth market, provides new lab capabilities

Getty Images

News | Breast Imaging | January 06, 2021
January 6, 2021 — Hologic, Inc., a global leader in women's...
Smart Breast Corporation (SmartBreast), a privately held company focused on breast cancer screening and detection, announced today that it has acquired certain molecular breast imaging (MBI) assets from Dilon Technologies, Inc. (Dilon) for an undisclosed amount.
News | Breast Imaging | January 04, 2021
January 4, 2021 — Smart Breast Corporation (SmartBreast), a privately held company focused on...
#coronavirus #COVID19 #pandemic

Getty Images

News | Radiology Imaging | January 01, 2021
The Imaging Technology News (ITN) team wishes you a Happy and Healthy New Year!